AGCO Power: Forestry Machines Need Purpose-Built Off-Road Engines – Not Compromises
8.9.2026 08:00:00 CEST | Business Wire | Press Release
Modern forestry machines work in some of the most demanding conditions in the off-road world. Harvesters and forwarders operate far from workshops, under rapidly changing loads and in environments where uptime, fuel efficiency and serviceability have a direct impact on productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907908774/en/
Forestry applications place very different demands on an engine than on-road applications do,” says Juha Tervala, Managing Director at AGCO Power. Juha Tervala and Andreas Eurs, Product Manager at long-standing partner Logset, are pictured presenting Logset’s new 8H GTE 4.0 Hybrid harvester, powered by an AGCO Power engine.
For AGCO Power, the starting point is clear: a forestry machine needs an engine designed for demanding off-road applications.
“Forestry applications place very different demands on an engine than on-road applications do. The engine must respond instantly to changing loads, work seamlessly with the machine’s hydraulic and control systems, and keep it productive in conditions where downtime is costly,” says Juha Tervala, Managing Director at AGCO.
AGCO Power will present its modern diesel engines for demanding off-road applications at INTERFORST 2026, held at Messe München on 15–18 October. Visitors can find AGCO Power in the Systems & Components area, booth B6.141.
The CORE engine family combines fast load response, fuel efficiency, practical serviceability and long-term reliability. In forestry applications, these are not just technical characteristics, but factors that directly affect machine productivity and operating costs.
Designed for demanding off-road work
Forestry places very specific demands on an engine. In a harvester, the load changes rapidly as the head feeds, delimbs and cuts timber. In a forwarder, the engine must deliver controlled power when moving heavy loads over uneven terrain, slopes and soft ground.
In these conditions, reliable operation is not only about power and torque. The engine must also maintain dependable lubrication and performance when the machine is working on inclines or in tilted positions, as forestry machines often operate on uneven ground for extended periods.
“Performance in forestry is created by the whole machine. The engine, hydraulics, software and serviceability must be designed as one integrated system,” says Jarno Ratia, Director of Product Management of AGCO Power.
The CORE platform is designed around high torque, low engine speeds, efficiency and adaptability to different applications. Its architecture also supports future powertrain technologies such as hybridization and alternative fuels.
The modular CORE family currently includes three engine options for different power requirements: the four-cylinder CORE50, producing up to 165 kW and 950 Nm; the six-cylinder CORE75, producing up to 250 kW and 1,450 Nm; and the latest variant, CORE80, rated at 252 kW with maximum torque of 1,680 Nm.
Easy serviceability supports uptime
In forestry, serviceability is a direct part of productivity. Machines often operate long hours and far from service locations, so routine maintenance needs to be straightforward, and downtime kept to a minimum.
“Good serviceability supports both people and productivity. In cold, dark or remote conditions, a well-designed service layout makes routine maintenance more ergonomic and efficient, while helping the machine return to productive operation sooner,” says Ratia.
The technical architecture of the engine also affects serviceability and reliability. CORE engines achieve low emissions without exhaust gas recirculation, or EGR, and without two-stage turbocharging. This supports a simpler engine layout and reduces the number of components in the system.
Proven fuel efficiency in independent DLG PowerMix testing*
Fuel efficiency, demonstrated by independent DLG PowerMix tests (test reports 7547, 7552, 7435 and 7599), is an important advantage of AGCO Power’s modern CORE engines. Although DLG PowerMix is a tractor test rather than a forestry-machine test, the results provide independent evidence of the efficiency of the CORE engine platform across different load points and engine-speed ranges.
The results also demonstrate the importance of powertrain integration. Fuel efficiency is not determined by the engine alone, but by how the engine, transmission, hydraulics and software work together in the complete machine.
“Lower fuel consumption immediately affects operating costs. But efficiency cannot come at the expense of response, durability or uptime. That balance is where AGCO Power’s off-road experience makes the difference,” says Ratia.
AGCO Power at INTERFORST
International Key Trade Fair for Forestry and Forest
Messe München, 15–18 October 2026
Systems & Components
Booth B6.141
About AGCO Power
AGCO Power is one of the world’s leading developers and manufacturers of engines for off-road machines. We produce engines for well-known tractor brands such as Fendt, Valtra, and Massey Ferguson. In addition to these, AGCO Power engines are used in other off-road machines, including forestry equipment. Production facilities are located in Finland, China, Brazil, and Argentina. The Linnavuori plant has been operating for over 80 years and is a subsidiary of AGCO Corporation. www.agcopower.com.
About AGCO
AGCO (NYSE: AGCO) is a global leader in agricultural machinery and precision agriculture technologies. Driven by a Farmer-First strategy, AGCO delivers value through its differentiated leading brands, Fendt™, Massey Ferguson™, PTx™ and Valtra™. AGCO’s high-performance equipment and smart farming solutions, including brand-agnostic retrofit technologies and autonomous offerings, empower farmers to drive productivity while sustainably feeding the world. For more information, visit www.agcocorp.com.
*Source material for DLG PowerMix tests
- Fendt 620 Vario with the CORE50 engine, DLG Test Report 7547
- Fendt 724 Vario Gen7.1 with the CORE75 engine, DLG Test Report 7552
- Fendt 728 Vario Gen7 with the CORE75, DLG Test Report 7435
- Fendt 832 Vario with the CORE80 engine, DLG Test Report 7599
View source version on businesswire.com: https://www.businesswire.com/news/home/20260907908774/en/
Contacts
For more information and interview requests:
Communications Manager Vilja Pylsy, vilja.pylsy@agcocorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom